MAIL MAN

[righty]

OTCMB FEATURED COMPANY NEWS: Vivakor (VIVK) Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
Mon, December 14, 2009 5:54:11 AMFrom: "[e-mail]" <[e-mail]>Add to Contacts



--------------------------------------------------------------------------------









Latest Breaking Company News

At OTCMarketBulls.com, we look to find the highest potential companies, preferably at a bottom. We look to bring you real companies with real products/ services; strong business plans, with a strong desire to achieve this goal.




Stay Current and Follow us on Twitter!








Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
Dec 14, 2009 6:00:00 AM



CORALVILLE, Iowa, Dec. 14 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the launch of its new website promoting its remarkable VivaThermic Vial at www.vivathermic.com. In addition to providing customers with the latest news and developments for its VivaThermic product line, Vivakor developed this site to be a valuable resource for its domestic and international customers, such as the highly respected Veritas Corporation of Tokyo, Japan, which signed an exclusive five year exclusive distribution agreement to distribute Vivakor's VivaThermic products in Japan. Under the terms of the Agreement, Veritas will have exclusive distribution rights to all Vivakor's VivaThermic Division products in Japan, including the recently released VivaThermic SUPER-150 and VivaThermic UTLRA-300 cryovials.



Mr. Shinsaku Iida, President of Veritas Corporation, stated: "As a leading distributor of a biotech products in Japan, including capital equipment, reagents, and kits to support research in the fields of genomics, proteomics, and metabolomics, we believe we are the perfect partner for Vivakor and their VivaThermic product line. In Japan, as in the rest of the world, there is a real need for better sample preparation methods that will allow for the safe, rapid, and reliable sample preservation from a variety of biomaterials. We are very impressed with new Ultra CryoVials, believe that it is the best system available for sample preservation, and believe that we will be very successful in placing the entire cryo-preservation system in the Japanese market as 21 century's gold standard."



Vivakor's CEO, Dr. Tannin Fuja, indicated that, "We are pleased to launch the VivaThermic website that will not only promote domestic distribution but assist our international distributors. We are also pleased to partner with the highly-respected Japanese corporation, Veritas, to distribute our superior VivaThermic products. The Japanese biotechnology industry is one of the leading participants in the global biotech market. Japan, with its family of industry leading biotechnology companies, continues to lead in this increasingly global market."



About Vivakor



Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.



About Veritas Corporation



Veritas is a trusted distributor of cutting edge products from around the world to the Japanese life science community. Established in 1972, Veritas is well known for superior technical support and knowledgeable sales and marketing staff. In addition to Vivakor's VivaThermic products, Veritas represents prestigious suppliers from USA, Canada, Germany, England, Sweden, Italy, New Zealand, China, and India for life science products. Veritas specializes in cell biology (including stem cell biology), immunology, hematology and microbiology, as well as to sophisticated scientific instruments and niche services.



FORWARD-LOOKING STATEMENTS



This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.



Contact: Vivakor Investor Relations c/o IME Advisors (888) 648-848
SOURCE Vivakor, Inc.


----------------------------------------------
Vivakor Investor Relations c/o IME Advisors [phone]





This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended and such Forward Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the Company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the Company's operating results and financial condition; and other risks detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.




Contact:Shelley SchonfeldVPPhone: [phone]Email: [e-mail]

Disclaimer Release Of Liability: OTCMarketBulls.com is an independent electronic publication, which provides industry data and information on publicly traded companies for the use of our readers. All material herein is information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by OTCMarketBulls.com to be accurate, and should not be considered to be all-inclusive. This profile contains forward-looking statements that involve risks and uncertainties. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward looking statements. Statements in this press release about the companys future expectation! s other than historical facts, are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Act of 1934, as that term is defined in the Private Securities Reform Act of 1995. Investors are cautioned that any information in this communication contains certain such forward-looking statements that involve substantial risks and uncertainties. When used, the words "anticipate," "believe," "estimate," "expect," and similar expressions, as they relate to the company or its management, are intended to identify such forward-looking statements. The company's actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward looking statements. Such "forward-looking statements" are subject to risks and uncertainties set forth from time to time in the companys SEC reports that could cause results to differ materially from those expressed or implied include, but are not limited to, the results of future tests and the availability of funding for additional research and development. This material is for informat ional purposes only and should NOT be construed as an offer or solicitation of an offer to buy or sell any se cur ities. OTCMarketBulls may liqu idate any securities issued when deemed appropriate to do so. Such liquidation may have a negative impact on the securities being liquidated. OTCMarketBulls is not a licensed broker, broker dealer, market marker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on www.otcmarketbulls.com. OTCMarketBulls and/or its affiliates have received fifty thousand dollars from a third party for advertising. OTCMarketBulls affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise! in value. OTCMarketBulls does not and will not offer any opinion as to when others should sell; each investor must make that decision.











Please Click here to unsubscribe OTC Newsletter.